Asset Management One’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$63.4M Sell
141,949
-8,157
-5% -$3.8M 0.19% 96
2025
Q4
$69M Buy
150,106
+3,242
+2% +$1.4M 0.19% 96
2025
Q3
$57.5M Buy
146,864
+5,303
+4% +$2.22M 0.17% 111
2025
Q2
$63M Sell
141,561
-312
-0.2% -$144K 0.2% 96
2025
Q1
$68.8M Buy
141,873
+6,590
+5% +$3.07M 0.24% 84
2024
Q4
$55.3M Buy
135,283
+96
+0.1% +$44.5K 0.19% 99
2024
Q3
$62.9M Buy
135,187
+1,427
+1% +$685K 0.22% 85
2024
Q2
$62.7M Sell
133,760
-5,049
-4% -$2.19M 0.24% 79
2024
Q1
$58M Sell
138,809
-3,848
-3% -$1.63M 0.22% 86
2023
Q4
$58.4M Buy
142,657
+16,559
+13% +$6.12M 0.24% 85
2023
Q3
$43.8M Buy
126,098
+375
+0.3% +$131K 0.2% 99
2023
Q2
$44.2M Sell
125,723
-1,190
-0.9% -$401K 0.19% 103
2023
Q1
$40M Buy
126,913
+7,978
+7% +$2.39M 0.18% 114
2022
Q4
$34.4M Sell
118,935
-7,130
-6% -$2.17M 0.17% 127
2022
Q3
$36.5M Sell
126,065
-3,129
-2% -$900K 0.19% 111
2022
Q2
$36.4M Sell
129,194
-25,819
-17% -$6.91M 0.17% 124
2022
Q1
$40.5M Sell
155,013
-15,309
-9% -$3.63M 0.16% 130
2021
Q4
$38M Buy
170,322
+13,382
+9% +$2.6M 0.13% 152
2021
Q3
$28.5M Sell
156,940
-5,381
-3% -$1.05M 0.11% 190
2021
Q2
$32.7M Buy
162,321
+4,801
+3% +$1M 0.12% 174
2021
Q1
$33.8M Sell
157,520
-2,167
-1% -$476K 0.13% 153
2020
Q4
$37.3M Buy
159,687
+21,644
+16% +$4.97M 0.15% 135
2020
Q3
$37.6M Sell
138,043
-4,034
-3% -$1.11M 0.17% 112
2020
Q2
$41.2M Buy
142,077
+970
+0.7% +$263K 0.2% 99
2020
Q1
$33.6M Sell
141,107
-329
-0.2% -$75.5K 0.2% 105
2019
Q4
$31M Buy
141,436
+570
+0.4% +$115K 0.14% 159
2019
Q3
$23.9M Buy
140,866
+3,970
+3% +$702K 0.12% 198
2019
Q2
$25.1M Buy
136,896
+11,789
+9% +$2.06M 0.12% 177
2019
Q1
$23M Sell
125,107
-292,016
-70% -$53.9M 0.12% 170
2018
Q4
$69M Buy
417,123
+1,566
+0.4% +$271K 0.16% 138
2018
Q3
$80M Sell
415,557
-1,591
-0.4% -$283K 0.16% 137
2018
Q2
$70.2M Buy
417,148
+22,425
+6% +$3.48M 0.15% 154
2018
Q1
$64.3M Buy
394,723
+4,966
+1% +$811K 0.14% 164
2017
Q4
$58.4M Sell
389,757
-1,456
-0.4% -$216K 0.13% 175
2017
Q3
$59.4M Buy
391,213
+7,896
+2% +$1.19M 0.14% 164
2017
Q2
$49.4M Sell
383,317
-5,344
-1% -$643K 0.13% 184
2017
Q1
$42.5M Sell
388,661
-33,569
-8% -$2.96M 0.11% 212
2016
Q4
$31.1M Buy
422,230
+353,190
+512% +$28.7M 0.08% 283
2016
Q3
$5.88M Sell
69,040
-2,251
-3% -$213K 0.09% 259
2016
Q2
$6.06M Sell
71,291
-7,359
-9% -$636K 0.09% 245
2016
Q1
$6.17M Sell
78,650
-20,373
-21% -$1.84M 0.09% 249
2015
Q4
$12.7M Sell
99,023
-5,652
-5% -$682K 0.19% 125
2015
Q3
$10.5M Sell
104,675
-7,979
-7% -$1.03M 0.16% 148
2015
Q2
$13.8M Sell
112,654
-2,494
-2% -$314K 0.19% 122
2015
Q1
$13.9M Buy
115,148
+10,244
+10% +$1.23M 0.17% 140
2014
Q4
$12.6M Buy
104,904
+3,516
+3% +$396K 0.16% 149
2014
Q3
$11.5M Buy
101,388
+75,072
+285% +$7.15M 0.16% 146
2014
Q2
$2.47M Buy
26,316
+1,074
+4% +$75.3K 0.04% 488
2014
Q1
$1.72M Sell
25,242
-11,794
-32% -$934K 0.03% 568
2013
Q4
$2.73M Sell
37,036
-439
-1% -$30.6K 0.04% 428
2013
Q3
$2.85M Sell
37,475
-3,356
-8% -$267K 0.04% 419
2013
Q2
$3.29M Buy
+40,831
New +$3.01M 0.05% 341

Other funds holding VRTX

Asset Management One's VRTX Position: Q1 2026 in Review

Asset Management One reduced its Vertex Pharmaceuticals (VRTX) stake by 5.4% in Q1 2026, selling an estimated $3.8M and leaving 141,949 shares worth $63.4M. The position accounts for 0.19% of the portfolio, ranked #96.

Asset Management One first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $80M in Q3 2018. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Asset Management One held 141,949 shares of Vertex Pharmaceuticals worth $63.4M as of Q1 2026.
  • Asset Management One sold 8,157 Vertex Pharmaceuticals shares in Q1 2026, an estimated $3.8M.
  • Vertex Pharmaceuticals made up 0.19% of Asset Management One's portfolio in Q1 2026, its #96 holding.
  • Asset Management One first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Asset Management One's Vertex Pharmaceuticals position peaked at $80M in Q3 2018.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Asset Management One's 13F filing for Q1 2026, filed 8 May 2026.